ICON Public Limited (NASDAQ:ICLR) Receives Consensus Rating of “Moderate Buy” from Brokerages

ICON Public Limited (NASDAQ:ICLRGet Free Report) has received a consensus rating of “Moderate Buy” from the fifteen brokerages that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $287.00.

A number of research analysts recently weighed in on the company. Barclays dropped their price target on ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. JPMorgan Chase & Co. dropped their price target on shares of ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Robert W. Baird reduced their price objective on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research note on Wednesday, November 20th. Baird R W downgraded shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Finally, Evercore ISI decreased their price objective on ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Read Our Latest Report on ICLR

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Sierra Ocean LLC bought a new stake in ICON Public during the fourth quarter worth about $29,000. Park Place Capital Corp boosted its position in ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after buying an additional 166 shares during the period. GAMMA Investing LLC grew its stake in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in shares of ICON Public by 23.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after buying an additional 96 shares during the last quarter. Finally, First Horizon Advisors Inc. increased its position in ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 151 shares during the period. 95.61% of the stock is currently owned by institutional investors.

ICON Public Stock Performance

NASDAQ:ICLR opened at $199.08 on Monday. The company has a fifty day moving average of $209.33 and a 200-day moving average of $258.43. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72. The firm has a market capitalization of $16.42 billion, a P/E ratio of 22.19, a P/E/G ratio of 1.78 and a beta of 1.20. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35.

ICON Public Company Profile

(Get Free Report

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Stories

Analyst Recommendations for ICON Public (NASDAQ:ICLR)

Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.